Evaluation of the antidiabetic potential of selected medicinal plant extracts from the Canadian boreal forest used to treat symptoms of diabetes: part II

Abstract
Among the Cree of northern Quebec, the disproportionately high rate of diabetic complications is largely due to the cultural inadequacy of modern therapies for type 2 diabetes. To establish culturally adapted antidiabetic treatments, our team identified several candidate plant species used by the Cree to treat symptoms of diabetes. An initial study focused on 8 species and revealed that most possess significant in vitro antidiabetic activity. The purpose of the present study was to assess a further 9 species identified through the ethnobotanical survey. Crude plant extracts were screened for (i) potentiation of basal and insulin-stimulated glucose uptake by skeletal muscle cells (C2C12) and adipocytes (3T3-L1); (ii) potentiation of glucose-stimulated insulin secretion by pancreatic β cells (βTC); (iii) potentiation of adipogenesis in 3T3-L1 cells; (iv) protection against glucose toxicity and glucose deprivation in PC12-AC neuronal precursor cells; and (v) diphenylpicrylhydrazyl (DPPH) oxygen free radical scavenging. Four species potentiated basal glucose uptake in muscle cells or adipocytes, one species being as potent as metformin. Adipogenesis was accelerated by 4 species with a potency roughly half that of rosiglitazone. Five species protected PC12-AC cells against glucose toxicity and 4 protected against glucose deprivation. Five species exhibited antioxidant activity comparable to ascorbic acid. However, no species increased insulin secretion. The present study revealed that Gaultheria hispidula , Rhododendron tomentosum , and Vaccinium vitis-idaea exhibit a promising profile of antidiabetic potential and are good candidates for more in-depth evaluation.

This publication has 43 references indexed in Scilit: